Patents by Inventor Kara Olson

Kara Olson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240158529
    Abstract: CD38 is expressed on malignant plasma cells. CD28 is a costimulatory molecule required for T-cell activation and survival. Provided herein are novel anti-CD38 antibodies, anti-CD28 antibodies, and bispecific antibodies (bsAbs) that bind to both CD38 and CD28 and act as costimulatory agents to activate T cells via binding CD80 and/or CD86. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing CD38. The bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced CD38-targeted immune response is desired and/or therapeutically beneficial. For example, the bispecific antibodies of the invention are useful for the treatment of various cancers, including multiple myeloma, lymphoma, and leukemia.
    Type: Application
    Filed: January 23, 2024
    Publication date: May 16, 2024
    Inventors: David DiLillo, Aynur Hermann, Jessica Kirshner, Kara Olson, Olga Sineshchekova, Eric Smith, Erica Ullman
  • Patent number: 11905332
    Abstract: CD38 is expressed on malignant plasma cells. CD28 is a costimulatory molecule required for T-cell activation and survival. Provided herein are novel anti-CD38 antibodies, anti-CD28 antibodies, and bispecific antibodies (bsAbs) that bind to both CD38 and CD28 and act as costimulatory agents to activate T cells via binding CD80 and/or CD86. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing CD38. The bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced CD38-targeted immune response is desired and/or therapeutically beneficial. For example, the bispecific antibodies of the invention are useful for the treatment of various cancers, including multiple myeloma, lymphoma, and leukemia.
    Type: Grant
    Filed: September 17, 2021
    Date of Patent: February 20, 2024
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: David DiLillo, Aynur Hermann, Jessica Kirshner, Kara Olson, Olga Sineshchekova, Eric Smith, Erica Ullman
  • Publication number: 20230416396
    Abstract: CD38 is expressed on malignant plasma cells. 4-1BB is a costimulatory molecule required for T-cell activation and survival. Provided herein are novel multispecific antigen binding molecules (MABMs) that bind to both CD38 and 4-1BB, for example, to provide “signal 2” in order to enhance the activation of T cells in the presence of a “signal 1”, provided by a Tumor-associated antigen (TAA)×CD3 bispecific antibody or an allogeneic response provided by an antigen presenting cell. In certain embodiments, the multispecific antigen binding molecules of the present invention are capable of inhibiting the growth of tumors expressing CD38. The multispecific antigen binding molecules of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced CD38-targeted immune response is desired and/or therapeutically beneficial.
    Type: Application
    Filed: May 17, 2023
    Publication date: December 28, 2023
    Inventors: Robert Babb, David DiLillo, Aynur Hermann, Kara Olson, Yang Shen, Erica Ullman
  • Publication number: 20230357446
    Abstract: Provided herein are methods of mediating killing of a tumor cell by administering to the subject a multispecific antigen binding molecule with a first antigen binding region specific for first target antigen and a second antigen binding region specific for a CD28 protein. In some embodiments, the tumor cell does not express the target antigen. In some embodiments, the tumor cell is not predicted to express the target antigen.
    Type: Application
    Filed: April 11, 2023
    Publication date: November 9, 2023
    Inventors: Eric Smith, Dimitris Skokos, Kara Olson, Lauric Haber, Joyce Wei, Chia-yang Lin
  • Publication number: 20230174652
    Abstract: The present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD28, and a second antigen-binding molecule that specifically binds human CD-22. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing CD-22, such as B-cell lymphomas. The antibodies and bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an up-regulated or induced targeted immune response is desired and/or therapeutically beneficial.
    Type: Application
    Filed: June 21, 2022
    Publication date: June 8, 2023
    Inventors: Andrew J. Murphy, Dimitris Skokos, Janelle Waite, Erica Ullman, Aynur Hermann, Eric Smith, Kara Olson, Joyce Wei, George D. Yancopoulos
  • Publication number: 20220306758
    Abstract: B-cell maturation antigen (BCMA) is expressed on malignant plasma cells. The present invention provides novel bispecific antibodies (bsAbs) that bind to both BCMA and CD3 and activate T cells via the CD3 complex in the presence of BCMA-expressing tumor cells. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing BCMA. The bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced BCMA-targeted immune response is desired and/or therapeutically beneficial. For example, the bispecific antibodies of the invention are useful for the treatment of various cancers, including multiple myeloma.
    Type: Application
    Filed: May 31, 2022
    Publication date: September 29, 2022
    Inventors: Eric Smith, Kara Olson, Frank Delfino, David DiLillo, Jessica Kirshner, Olga Sineshchekova, Qian Zhang
  • Publication number: 20220233690
    Abstract: The present invention provides compositions and methods for treating cancer and inhibiting cytokine release syndrome (CRS). The methods of the present invention comprise administering to a subject in need thereof a therapeutically effective amount of a CD40 antagonist or a CAR-T cell expressing a CD40 antagonist in combination with a therapeutically effective amount of a CD3 multispecific antigen binding molecule.
    Type: Application
    Filed: January 28, 2022
    Publication date: July 28, 2022
    Inventors: Kara OLSON, Olga Sineshchekova, Eric Smith, Chiayang Lin
  • Patent number: 11396544
    Abstract: The present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD28, and a second antigen-binding molecule that specifically binds human CD-22. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing CD-22, such as B-cell lymphomas. The antibodies and bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an up-regulated or induced targeted immune response is desired and/or therapeutically beneficial.
    Type: Grant
    Filed: December 18, 2019
    Date of Patent: July 26, 2022
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Andrew J. Murphy, Dimitris Skokos, Janelle Waite, Erica Ullman, Aynur Hermann, Eric Smith, Kara Olson, Joyce Wei, George D. Yancopoulos
  • Patent number: 11384153
    Abstract: B-cell maturation antigen (BCMA) is expressed on malignant plasma cells. The present invention provides novel bispecific antibodies (bsAbs) that bind to both BCMA and CD3 and activate T cells via the CD3 complex in the presence of BCMA-expressing tumor cells. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing BCMA. The bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced BCMA-targeted immune response is desired and/or therapeutically beneficial. For example, the bispecific antibodies of the invention are useful for the treatment of various cancers, including multiple myeloma.
    Type: Grant
    Filed: July 18, 2019
    Date of Patent: July 12, 2022
    Assignee: Regeneran Pharmaceuticals, Inc.
    Inventors: Eric Smith, Kara Olson, Frank Delfino, David DiLillo, Jessica Kirshner, Olga Sineshchekova, Qian Zhang
  • Publication number: 20220089766
    Abstract: CD38 is expressed on malignant plasma cells. CD28 is a costimulatory molecule required for T-cell activation and survival. Provided herein are novel anti-CD38 antibodies, anti-CD28 antibodies, and bispecific antibodies (bsAbs) that bind to both CD38 and CD28 and act as costimulatory agents to activate T cells via binding CD80 and/or CD86. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing CD38. The bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced CD38-targeted immune response is desired and/or therapeutically beneficial. For example, the bispecific antibodies of the invention are useful for the treatment of various cancers, including multiple myeloma, lymphoma, and leukemia.
    Type: Application
    Filed: September 17, 2021
    Publication date: March 24, 2022
    Inventors: David DiLillo, Aynur Hermann, Jessica Kirshner, Kara Olson, Olga Sineshchekova, Eric Smith, Erica Ullman
  • Publication number: 20200239576
    Abstract: The present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD28, and a second antigen-binding molecule that specifically binds human CD-22. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing CD-22, such as B-cell lymphomas. The antibodies and bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an up-regulated or induced targeted immune response is desired and/or therapeutically beneficial.
    Type: Application
    Filed: December 18, 2019
    Publication date: July 30, 2020
    Inventors: Andrew J. Murphy, Dimitris Skokos, Janelle Waite, Erica Ullman, Aynur Hermann, Eric Smith, Kara Olson, Joyce Wei, George D. Yancopoulos
  • Publication number: 20200024356
    Abstract: B-cell maturation antigen (BCMA) is expressed on malignant plasma cells. The present invention provides novel bispecific antibodies (bsAbs) that bind to both BCMA and CD3 and activate T cells via the CD3 complex in the presence of BCMA-expressing tumor cells. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing BCMA. The bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced BCMA-targeted immune response is desired and/or therapeutically beneficial. For example, the bispecific antibodies of the invention are useful for the treatment of various cancers, including multiple myeloma.
    Type: Application
    Filed: July 18, 2019
    Publication date: January 23, 2020
    Inventors: Eric Smith, Kara Olson, Frank Delfino, David DiLillo, Jessica Kirshner, Olga Sineshchekova, Qian Zhang
  • Publication number: 20130259799
    Abstract: Antigen binding proteins that bind to human GM-CSF protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of GM-CSF to GM-CSFR, inhibit GM-CSF-induced proliferation and signaling of myeloid lineage cell lines and inhibit GM-CSF-induced activation of human monocytes.
    Type: Application
    Filed: June 11, 2013
    Publication date: October 3, 2013
    Inventors: Jacqueline A. Kirchner, Kenneth A. Brasel, Kara Olson, Jose Carlos Escobar, Dauphine Barone
  • Patent number: 8481704
    Abstract: Antigen binding proteins that bind to human GM-CSF protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of GM-CSF to GM-CSFR, inhibit GM-CSF-induced proliferation and signaling of myeloid lineage cell lines and inhibit GM-CSF-induced activation of human monocytes.
    Type: Grant
    Filed: August 20, 2012
    Date of Patent: July 9, 2013
    Assignee: Amgen Inc.
    Inventors: Jacqueline A. Kirchner, Kenneth A. Brasel, Kara Olson, Jose Carlos Escobar, Dauphine Barone
  • Publication number: 20130071923
    Abstract: Antigen binding proteins that bind to human GM-CSF protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of GM-CSF to GM-CSFR, inhibit GM-CSF-induced proliferation and signaling of myeloid lineage cell lines and inhibit GM-CSF-induced activation of human monocytes.
    Type: Application
    Filed: August 20, 2012
    Publication date: March 21, 2013
    Applicant: Amgen Inc.
    Inventors: Jacqueline A. Kirchner, Kenneth A. Brasel, Kara Olson, Jose Carlos Escobar, Dauphine Barone
  • Patent number: 8268311
    Abstract: Antigen binding proteins that bind to human GM-CSF protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of GM-CSF to GM-CSFR, inhibit GM-CSF-induced proliferation and signaling of myeloid lineage cell lines and inhibit GM-CSF-induced activation of human monocytes.
    Type: Grant
    Filed: September 18, 2008
    Date of Patent: September 18, 2012
    Assignee: Amgen Inc.
    Inventors: Jacqueline A. Kirchner, Kenneth A. Brasel, Kara Olson, Jose Carlos Escobar, Dauphine Barone
  • Publication number: 20110189082
    Abstract: Antigen binding proteins that bind to human GM-CSF protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of GM-CSF to GM-CSFR, inhibit GM-CSF-induced proliferation and signaling of myeloid lineage cell lines and inhibit GM-CSF-induced activation of human monocytes.
    Type: Application
    Filed: September 18, 2008
    Publication date: August 4, 2011
    Inventors: Jacqueline A. Kirchner, Kenneth A. Brasel, Kara Olson, Jose Carlos Escobar, Dauphine Barone